Felipe Couñago1,2,3, Claudio Martínez-Ballesteros4, Carlos Artigas5, Ana Aurora Díaz-Gavela1,2,3, Luis Leonardo Guerrero Gómez1,2, María Eugenia Lillo-García6, José Reinaldo Chicharo6, Manuel Recio7, Antonio Maldonado8, Israel J Thuissard9, Cristina Andreu-Vázquez10, David Sanz-Rosa3, Antonio José Conde-Moreno11, Francisco José Marcos1,2,3, Sofía Sánchez García1,2, Juan Ignacio Martínez-Salamanca4, Joaquin Carballido-Rodríguez4, Javier Hornedo12, Elia Del Cerro1,2,3. 1. Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain. 2. Department of Radiation Oncology, Hospital La Luz, Madrid, 28003, Spain. 3. Clinical Department, Faculty of Biomedicine,Universidad Europea, Madrid, 28670, Spain. 4. Department of Urology, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain. 5. Department of Nuclear Medicine, Jules Bordet Institute, 1000, Bruselas, Belgium. 6. Unidad de Imagen Molecular, Centro de Investigaciones Medico-Sanitarias (CIMES), Fundación General de la Universidad de Málaga, Málaga, 29010, Spain. 7. Department of Radiology, Hospital Universitario Quirónsalud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain. 8. Department of Nuclear Medicine, Hospital Universitario Quirónsalud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain. 9. Department of Research, Universidad Europea, Madrid, 28670, Spain. 10. Department of Pharmacy, Biotechnology and Nutrition. Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, 28670, Spain. 11. Department of Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain. 12. Department of Medical Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
Abstract
AIM: To evaluate whether positron-emission tomography/computed tomography with 68Ga-PSMA (68Ga-PSMA PET/CT) influences the therapeutic management of patients with primary or recurrent prostate cancer (PCa). BACKGROUND: Although 68Ga-PSMA PET/CT is one of the best options for staging or restaging patients with PCa, its availability is still very limited in Spain. The present study reports the results of the first group of patients in Spain who underwent 68Ga-PSMA PET/CT imaging. MATERIALS AND METHODS: All patients (n = 27) with a histological diagnosis of PCa who underwent 68Ga-PSMA PET/CT prior to the definitive treatment decision at the only centre with this technology in Spain during 2017-2018 were included. Two nuclear medicine physicians and a radiologist reviewed the imaging studies. The clinical impact was assessed from a theoretical perspective, based on the treatment that would have been applied if no data from the 68Ga-PSMA PET/CT were available. RESULTS: Most patients (n = 26; 96%) had persistent disease or biochemical recurrence after radical prostatectomy, radiotherapy, or combined treatment. One patient underwent 68Ga-PSMA PET/CT imaging to stage high-risk PCa. Overall, 68Ga-PSMA PET/CT was positive in 19 patients (70.4%). In 68.75% of these patients, none of the other imaging tests-MRI, CT, or bone scans-performed prior to the 68Ga-PSMA PET/CT were able to detect the presence of cancerous lesions. Overall, the findings of the 68Ga-PSMA PET/CT led to a modification of the therapeutic approach in 62.96% of the patients in the study. CONCLUSIONS: 68Ga-PSMA PET/CT alters the therapeutic approach in a substantial proportion of patients with PCa.
AIM: To evaluate whether positron-emission tomography/computed tomography with 68Ga-PSMA (68Ga-PSMA PET/CT) influences the therapeutic management of patients with primary or recurrent prostate cancer (PCa). BACKGROUND: Although 68Ga-PSMA PET/CT is one of the best options for staging or restaging patients with PCa, its availability is still very limited in Spain. The present study reports the results of the first group of patients in Spain who underwent 68Ga-PSMA PET/CT imaging. MATERIALS AND METHODS: All patients (n = 27) with a histological diagnosis of PCa who underwent 68Ga-PSMA PET/CT prior to the definitive treatment decision at the only centre with this technology in Spain during 2017-2018 were included. Two nuclear medicine physicians and a radiologist reviewed the imaging studies. The clinical impact was assessed from a theoretical perspective, based on the treatment that would have been applied if no data from the 68Ga-PSMA PET/CT were available. RESULTS: Most patients (n = 26; 96%) had persistent disease or biochemical recurrence after radical prostatectomy, radiotherapy, or combined treatment. One patient underwent 68Ga-PSMA PET/CT imaging to stage high-risk PCa. Overall, 68Ga-PSMA PET/CT was positive in 19 patients (70.4%). In 68.75% of these patients, none of the other imaging tests-MRI, CT, or bone scans-performed prior to the 68Ga-PSMA PET/CT were able to detect the presence of cancerous lesions. Overall, the findings of the 68Ga-PSMA PET/CT led to a modification of the therapeutic approach in 62.96% of the patients in the study. CONCLUSIONS: 68Ga-PSMA PET/CT alters the therapeutic approach in a substantial proportion of patients with PCa.
Authors: C Artigas; J Alexiou; C Garcia; Z Wimana; F-X Otte; T Gil; R Van Velthoven; P Flamen Journal: Eur J Nucl Med Mol Imaging Date: 2015-10-27 Impact factor: 9.236
Authors: Anna Katharina Seitz; Isabel Rauscher; Bernhard Haller; Markus Krönke; Sophia Luther; Matthias M Heck; Thomas Horn; Jürgen E Gschwend; Markus Schwaiger; Matthias Eiber; Tobias Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-28 Impact factor: 9.236
Authors: Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-15 Impact factor: 9.236
Authors: Carlos Artigas; N Plouznikoff; T Gil; I Duran Derijckere; M Herchuelz; I Libert; P Flamen Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-04 Impact factor: 9.236
Authors: Carlos Artigas; François-Xavier Otte; Marc Lemort; Roland van Velthoven; Patrick Flamen Journal: Clin Nucl Med Date: 2017-05 Impact factor: 7.794
Authors: Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-20 Impact factor: 9.236